Zodon

Zodon Chewable Tablets and Oral Solution contains the active ingredient Clindamycin and is indicated for the treatment of infected wounds and abscesses. It can also be used to treat oral cavity/dental infections caused by or associated with clindamycin sensitive species of Staphylococcus spp, Streptococcus spp in dogs.

Zodon Chewable Tablets are clover-shaped beige tablets that have been scored so that they can be broken into four equal parts. The Oral Solution is a clear, amber liquid that can be administered with the included 3ml graduated syringe.

Active Substance

Clindamycin (as hydrochloride).

Indications for Use

Infections caused by clindamycin sensitive germs. In cats: For the treatment of infected wounds and abscesses caused by clindamycin sensitive species of Staphylococcus spp. and Streptococcus spp. In dogs: For the treatment of infected wounds, abscesses and oral cavity/dental infections caused by or associated with clindamycin sensitive species of Staphylococcus spp. , Streptococcus spp. , (except Streptococcus faecalis*), Bacteroides spp. , Fusobacterium necrophorum, Clostridium perfringens, for treatment of superficial pyoderma*, for the treatment of osteomyelitis caused by Staphylococcus aureus.

Contraindications

Clindamycin should not be administered to hamsters, guinea pigs, rabbits, chinchillas, horses or ruminants as clindamycin ingestion in those species could cause severe digestive disorders. Do not use in cases of hypersensitivity to either clindamycin or lincomycin, or to any of the excipients.

Special Warnings for Each Target Species

None

Special Precautions for Use in Animals

Inappropriate use of the product may increase the prevalence of bacteria resistant to clindamycin. Whenever possible, clindamycin should only be used based on susceptibility testing including the D-zone test. Official, national and local antimicrobial policies should be taken into account when the product is used. Clindamycin shows parallel-resistance with lincomycin and co-resistance with erythromycin. There is a partial cross-resistance to erythromycin and other macrolides. In case of administration of high doses of clindamycin or during prolonged therapy of one month or greater, tests for liver and renal functions and blood counts should be performed periodically. In dogs and cats with kidney problems and/or liver problems, accompanies by severe metabolic aberrations, the dose to be administered should be carefully determined and their condition should be monitored by performing appropriate blood tests during treatment. The use of the product is not recommended in neonates. The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals and children.

Special Precautions to be Taken by the Person Administering the Veterinary Medicinal Product to Animals

Wash hands carefully after use. People with known hypersensitivity to lincosamides (lincomycin and clindamycin) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse Reactions

Vomiting and/or diarrhoea have been observed. Clindamycin is likely to favour the proliferation non-susceptible organisms such as resistant Clostridia spp., and yeasts. In case of secondary infection, appropriate corrective measures should be taken based on clinical observations.

Use During Pregnancy and Lactation

When high dose studies in rats suggests that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, the safety of the veterinary medicinal product in pregnant bitches/queens or breeding male dogs/cats has not been established. Use only according to the benefit/risk assessment by the responsible veterinarian. Clindamycin can pass the placenta and blood-milk barrier. As a consequence, treatment of lactating females can cause diarrhoea in puppies and kittens.